Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has shown durable weight loss effects in clinical trials lasting up to two years, with participants maintaining an average of 10% to 16% body weight reduction. Many patients wonder whether continuing this medication beyond the initial six-month mark remains safe and effective. PlexusDx offers evidence-based semaglutide therapy designed to support extended, personalized treatment protocols tailored to individual response patterns and genetic factors.
Semaglutide Treatment Duration: What Clinical Evidence Shows
Major cardiovascular outcome trials have tracked semaglutide use for 104 weeks or longer in adults with obesity and type 2 diabetes. These studies consistently demonstrated that the medication maintained its weight-lowering effect without unexpected safety signals emerging during the extended treatment window. Participants who remained on therapy experienced sustained metabolic improvements, including reductions in waist circumference, blood pressure, and cholesterol markers.
The STEP trials, which evaluated once-weekly semaglutide specifically for weight management, enrolled participants for 68 weeks of active treatment. Data showed that weight loss plateaued around week 20 but remained stable through the end of the study period. This pattern suggests that semaglutide does not produce unlimited weight loss; instead, it helps maintain a new, lower weight set point when the medication is continued at the appropriate dose.
How Your Dose May Evolve During Extended Semaglutide Therapy
Semaglutide dosing typically begins low and increases gradually over 4 to 6 weeks to allow the body to adjust and minimize nausea and gastrointestinal side effects. Once a therapeutic dose is reached, many patients maintain that same dose throughout their treatment course. However, individual responses vary based on metabolism, lifestyle changes, and genetic factors that influence GLP-1 receptor sensitivity.
PlexusDx uses the Precision Peptide Genetic Test to identify key variants in the GLP1R gene (rs6923761) and related pathways that predict how your body responds to semaglutide therapy. This genetic information helps determine whether you may benefit from staying at a standard maintenance dose or require dose adjustments during months 6 through 12 and beyond. Your dose may need to go up. Your price won't—PlexusDx charges a flat monthly rate regardless of dose level, ensuring transparent, predictable costs.
Safety Profile of Long-Term Semaglutide Use Beyond 6 Months
Adverse events reported in long-term semaglutide trials are predominantly gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. The frequency and severity of these side effects tend to diminish over time as the body adapts to the medication. Serious adverse events are rare and occur at similar rates between semaglutide and placebo groups in clinical trials, indicating that extended use does not substantially increase safety risk.
Patients considering semaglutide therapy beyond six months should remain under medical supervision and attend regular follow-up appointments to monitor weight progress, metabolic markers, and tolerability. PlexusDx compounded semaglutide is prepared by licensed 503A compounding pharmacies in all 50 states, and treatment is supported by personalized guidance based on your individual health profile and genetic predispositions. Stopping semaglutide after extended use typically results in weight regain unless lifestyle modifications are sustained, so ongoing treatment may be appropriate for many individuals.
Combining Semaglutide with Lifestyle Changes for Sustained Results
The most successful long-term weight loss outcomes occur when semaglutide is combined with consistent dietary adjustments, regular physical activity, and behavioral support. Semaglutide reduces appetite and improves satiety, making it easier to maintain a calorie deficit, but the medication works most effectively alongside these foundational habits. Research shows that participants who engage in structured nutrition counseling and exercise programs experience greater weight loss and better metabolic improvements than those relying on medication alone.
PlexusDx patients have access to precision health guidance informed by their genetic test results, which map 14 metabolic pathways and 150+ genetic insights related to appetite regulation, energy expenditure, and nutrient processing. This personalized approach helps you understand how your body responds to dietary choices and physical activity, making it easier to make sustainable changes that complement your semaglutide therapy. Starting at just $149 per month, PlexusDx semaglutide injection provides an affordable entry point to evidence-based weight management without membership fees or insurance requirements.
When to Consider Switching or Adding Another GLP-1 Compound
Some patients experience a plateau in weight loss after several months of semaglutide therapy, or their weight loss response may be suboptimal from the start. In these cases, switching to tirzepatide—a dual GLP-1 and GIP receptor agonist—may produce greater results. Tirzepatide activates an additional metabolic pathway (the GIP receptor) that semaglutide does not target, and clinical trials show it produces 20% to 24% body weight reduction compared to 13% to 18% for semaglutide alone.
PlexusDx offers compounded tirzepatide injection starting at $249 per month, as well as a GLP-Squared injection combining both semaglutide and tirzepatide for patients seeking a dual-pathway approach. Genetic testing can reveal whether your GLP1R or GIPR variants predict better response to one compound over the other. Work with your PlexusDx provider to assess whether continuing semaglutide, switching compounds, or exploring combination therapy makes sense for your individual situation after six months or beyond.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to take semaglutide for more than six months continuously?
Yes. Clinical trials have tracked semaglutide use for up to two years with consistent safety and efficacy data. Long-term adverse events are predominantly mild, gastrointestinal, and tend to diminish over time. PlexusDx provides ongoing medical supervision to ensure your extended semaglutide therapy remains appropriate for your health profile.
Will I continue losing weight if I stay on semaglutide beyond six months?
Most patients experience weight loss plateau around 4 to 6 months on semaglutide, then maintain that lower weight as long as they continue the medication. Significant new weight loss after the initial plateau is uncommon unless dose is increased or lifestyle factors change substantially. Stopping the medication typically leads to weight regain within months.
How much does extended semaglutide therapy cost with PlexusDx?
PlexusDx semaglutide injection starts at $149 per month and remains the same flat rate regardless of whether your dose increases during treatment. There are no membership fees, no insurance required, and HSA/FSA funds are eligible, making long-term therapy affordable and transparent.
What should I do if semaglutide stops working after six months?
Switching to tirzepatide or exploring a dual GLP-1/GIP compound may reignite weight loss by activating an additional metabolic receptor. PlexusDx Precision Peptide Genetic Test results can identify which medication pathway your body responds to best, informing your provider's recommendation for month 7 and beyond.
How does the PlexusDx genetic test help with long-term semaglutide therapy?
PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body processes GLP-1 therapy and manages weight regulation. This $99 add-on test (after first month) helps predict whether you'll respond robustly to semaglutide long-term or may benefit from dose adjustments or alternative compounds early in your treatment journey.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Will Insurance Ever Cover Ozempic for Weight Loss?
Is Hair Thinning a Side Effect of Ozempic? Understanding the Connection